Henry Schein (HSIC) Price Target Raised to $66.00

Henry Schein (NASDAQ:HSIC) had its price target increased by Morgan Stanley from $65.00 to $66.00 in a research report sent to investors on Tuesday. They currently have an underweight rating on the stock.

Several other research analysts also recently commented on the company. ValuEngine upgraded Henry Schein from a strong sell rating to a sell rating in a research note on Thursday, September 13th. Zacks Investment Research downgraded Henry Schein from a buy rating to a hold rating in a research note on Thursday, August 2nd. Leerink Swann set a $100.00 target price on Henry Schein and gave the stock a buy rating in a research note on Tuesday, August 7th. BidaskClub upgraded Henry Schein from a hold rating to a buy rating in a research note on Saturday, September 8th. Finally, Robert W. Baird lifted their target price on Henry Schein from $83.00 to $90.00 and gave the stock an outperform rating in a research note on Tuesday, August 7th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $83.83.

Shares of NASDAQ HSIC opened at $83.95 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 1.29 and a debt-to-equity ratio of 0.34. Henry Schein has a 12 month low of $62.56 and a 12 month high of $90.52. The company has a market cap of $13.02 billion, a PE ratio of 23.33, a price-to-earnings-growth ratio of 2.45 and a beta of 0.97.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Monday, August 6th. The company reported $1.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.03. Henry Schein had a return on equity of 20.40% and a net margin of 3.15%. The company had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.31 billion. During the same period in the previous year, the company posted $0.88 EPS. The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. On average, research analysts expect that Henry Schein will post 4.12 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can lifted its holdings in Henry Schein by 12.4% during the 3rd quarter. Bank of Montreal Can now owns 415,759 shares of the company’s stock worth $35,352,000 after purchasing an additional 46,006 shares during the last quarter. Pittenger & Anderson Inc. lifted its holdings in Henry Schein by 6.4% during the 3rd quarter. Pittenger & Anderson Inc. now owns 41,397 shares of the company’s stock worth $3,520,000 after purchasing an additional 2,505 shares during the last quarter. Bridge Creek Capital Management LLC lifted its holdings in Henry Schein by 2.1% during the 3rd quarter. Bridge Creek Capital Management LLC now owns 34,947 shares of the company’s stock worth $2,971,000 after purchasing an additional 705 shares during the last quarter. Contravisory Investment Management Inc. acquired a new stake in Henry Schein during the 3rd quarter worth approximately $381,000. Finally, JLB & Associates Inc. raised its holdings in Henry Schein by 1.9% in the 3rd quarter. JLB & Associates Inc. now owns 55,818 shares of the company’s stock valued at $4,746,000 after acquiring an additional 1,051 shares in the last quarter. 96.65% of the stock is owned by institutional investors and hedge funds.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Recommended Story: How Investors Use a Balance Sheet

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply